Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals is a Watertown, MA-based public pharmaceutical company (NASDAQ: TTPH) developing novel antibiotics to treat drug-resistant Gram-negative bacterial infections and address antimicrobial resistance.
- Company typePrivate
- Founded2006
- HeadquartersWatertown, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tetraphase Pharmaceuticals does
Tetraphase Pharmaceuticals is a publicly traded, clinical-stage pharmaceutical company founded in 2006 and headquartered in Watertown, Massachusetts, listed on NASDAQ under ticker TTPH. Its functional focus is the development of novel antibiotics against serious and drug-resistant Gram-negative bacterial infections, addressing the public-health challenge of antimicrobial resistance. The company operates what it describes as a 'dynamic drug engine' — a chemistry-driven platform built on tetracycline-derived small molecules intended to overcome bacterial resistance mechanisms; however, specific product names, pipeline candidates, and technical platform details are not disclosed in the supplied source material.
Tetraphase Pharmaceuticals firmographics
Firmographics- Name
- Tetraphase Pharmaceuticals
- Website
- https://tphase.com
- Company type
- Private
- Founded year
- 2006
- Headcount range
- 51–100 employees
- Short description
- Tetraphase Pharmaceuticals is a Watertown, MA-based public pharmaceutical company (NASDAQ: TTPH) developing novel antibiotics to treat drug-resistant Gram-negative bacterial infections and address antimicrobial resistance.
- Ownership category
- akta.pro rank
Tetraphase Pharmaceuticals industry classification
Industry- Product category
- Infectious Disease Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where Tetraphase Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Markets served
Tetraphase Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Tetraphase Pharmaceuticals product offering
Product offeringCore offering
Tetraphase Pharmaceuticals develops novel antibiotics using a proprietary drug discovery engine, with a primary focus on tetracycline-class antibiotics targeting serious and drug-resistant Gram-negative bacterial infections. The company's pipeline targets multiple significant disease categories associated with antimicrobial resistance, addressing high-need infectious disease indications for hospital and institutional healthcare customers.
Product overview
Tetraphase Pharmaceuticals is a pharmaceutical company focused on antibiotic development for Gram-negative bacteria. Based on the source data reviewed, no specific product names, drug candidates, or pipeline details were available in the provided sources. The company's primary focus is on developing antibiotics to address antimicrobial resistance (AMR), though no named products, platforms, or services are documented in the available materials.
Differentiator
Problem solved
Functional benefit
Products and services
- Novel tetracycline-class antibiotics targeting Gram-negative bacteria Proprietary antibiotic drug candidates developed through Tetraphase's drug discovery engine, intended for the treatment of serious and drug-resistant Gram-negative bacterial infections in hospital and institutional settings.
Companies that use Tetraphase Pharmaceuticals
Customer profileIdeal customer profiles1 record
Tetraphase Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Tetraphase Pharmaceuticals partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Tetraphase Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Paratek Pharmaceuticals: Paratek Pharmaceuticals is a specialty pharmaceutical company developing tetracycline-class antibiotics for serious community-acquired infections, including resistant pathogens. Like Tetraphase, Paratek is a small public anti-infective developer navigating the same challenging commercial antibiotic market.
- Melinta Therapeutics: Melinta Therapeutics develops and commercializes antibiotics for serious bacterial infections, including drug-resistant pathogens. As a small-cap public anti-infective specialist, Melinta competes directly with Tetraphase in the hospital antibiotic market addressing resistant Gram-negative bacteria.
- Entasis Therapeutics: Entasis Therapeutics is a clinical-stage biopharmaceutical company developing differentiated antibacterial products for serious infections caused by multidrug-resistant pathogens. Entasis targets the same AMR space as Tetraphase, including Gram-negative resistant bacteria.
- Nabriva Therapeutics: Nabriva Therapeutics is a biopharmaceutical company focused on developing novel antibiotics for serious infections, including those caused by resistant pathogens. Nabriva competes in the same anti-infective specialty market as Tetraphase.
- Cidara Therapeutics: Cidara Therapeutics is a biotechnology company developing novel anti-infectives, including antifungal and antibacterial agents. Cidara operates in the same anti-infective therapeutic space and faces similar market dynamics as Tetraphase.
- Summit Therapeutics: Summit Therapeutics has historically developed antibiotics targeting serious bacterial infections and C. difficile. As a small public biopharmaceutical company in the infectious disease space, Summit is comparable in scale and therapeutic focus to Tetraphase.
- Iterum Therapeutics: Iterum Therapeutics is a clinical-stage pharmaceutical company developing differentiated anti-infectives aimed at combatting antimicrobial resistance. Iterum targets similar resistant Gram-negative infections as Tetraphase.
Broad incumbents
- Achaogen: Achaogen was a biopharmaceutical company focused on developing antibiotics for multi-drug resistant Gram-negative infections. Its commercial trajectory (including post-approval commercial struggles) serves as a reference point for the structural challenges Tetraphase faces in the antibiotic market.
Emerging players
- VenatoRx Pharmaceuticals: VenatoRx Pharmaceuticals is a private clinical-stage pharmaceutical company developing antibiotics to address drug-resistant bacterial infections, including Gram-negative pathogens. VenatoRx targets the same AMR unmet need as Tetraphase and has similarly received CARB-X funding.
- Seres Therapeutics: Seres Therapeutics is a microbiome therapeutics company developing treatments for serious infectious diseases and inflammatory conditions. While focused on microbiome-based therapies rather than traditional antibiotics, Seres addresses adjacent AMR-related therapeutic opportunities.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Tetraphase Pharmaceuticals social profiles
Digital presenceTetraphase Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tetraphase Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
Tetraphase Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds7 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tetraphase Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tetraphase Pharmaceuticals
What does Tetraphase Pharmaceuticals do?
Tetraphase Pharmaceuticals develops novel antibiotics using a proprietary drug discovery engine, with a primary focus on tetracycline-class antibiotics targeting serious and drug-resistant Gram-negative bacterial infections. The company's pipeline targets multiple significant disease categories associated with antimicrobial resistance, addressing high-need infectious disease indications for hospital and institutional healthcare customers.
When was Tetraphase Pharmaceuticals founded?
Tetraphase Pharmaceuticals was founded in 2006. It employs 51 to 100 people.
Where is Tetraphase Pharmaceuticals based?
Tetraphase Pharmaceuticals is headquartered in Watertown, United States, in the North America region.
Who are Tetraphase Pharmaceuticals's main competitors?
Direct peers on record are Paratek Pharmaceuticals, Melinta Therapeutics, Entasis Therapeutics, Nabriva Therapeutics, Cidara Therapeutics, Summit Therapeutics and Iterum Therapeutics. Achaogen is listed as a broad incumbent. Emerging players are VenatoRx Pharmaceuticals and Seres Therapeutics.
Does Tetraphase Pharmaceuticals have an API?
No public API is recorded for Tetraphase Pharmaceuticals.
What industry is Tetraphase Pharmaceuticals in?
Tetraphase Pharmaceuticals's product category is Infectious Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325412 and its SIC code is 2834.